Phaseline

Targets › GATA2

GATA2 (Endothelial transcription factor GATA-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Dec 2027.

Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'. (UniProt, P23769)

Open in Phaseline: the race on GATA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Gene replacement therapy via allogeneic stem cell transplantation to restore functional GA
GATA2Phase 2GATA2Dec 2027

Conditions

GATA2 (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.